Fucosylated fraction of alpha‐fetoprotein, L3, as a useful prognostic factor in patients with hepatocellular carcinoma with special reference to low concentrations of serum alpha‐fetoprotein

Kobayashi, Makoto; Kuroiwa, Takashi; Suda, Takafumi; Tamura, Yasushi; Kawai, Hirokazu; Igarashi, Masato; Fukuhara, Yasuo; Aoyagi, Yoshinobu

doi:10.1111/j.1872-034x.2007.00147.x

Cited by 22 publications

(27 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We previously reported that AFP-L3-positive ([15%) patients had a lower survival rate than negative (\15%) patients in subgroups with a low serum AFP concentration. Moreover, the statistically significant differences were more distinct in the subgroups with lower AFP concentrations [20]. However, the patients in these studies had received various treatments such as hepatectomy, RFA, and transcatheter arterial embolization, and Fig.…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Fucosylated Fraction of Alpha-Fetoprotein as a Predictor of Prognosis in Patients with Hepatocellular Carcinoma After Curative Treatment

et al. 2009

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

“…AFP, AFP-L3, and DCP were measured in the same serum before treatment. Cut-off values for positivity for AFP, AFP-L3, and DCP were set at 20 ng/ml, 15%, and 40 mAU/ml, respectively, based on previous studies [18][19][20].…”

Section: Diagnosis Of Hcc and Laboratory Examinationmentioning

confidence: 99%

Fucosylated Fraction of Alpha-Fetoprotein as a Predictor of Prognosis in Patients with Hepatocellular Carcinoma After Curative Treatment

et al. 2009

Self Cite

View full text Add to dashboard Cite

show abstract

“…Accordingly, the limited usefulness of AFP-L3 at low AFP concentrations has been reported. On the other hand, Kobayashi et al [29] reported AFP-L3 to be an indicator of an unfavorable prognosis in HCC, even at very low serum AFP concentrations. In addition, Tada et al [30] recently stressed the relationship between AFP-L3 positivity and the pathological features of HCC.…”

Section: Discussionmentioning

confidence: 99%

A New Prognostic Staging System for Hepatocellular Carcinoma: Value of the Biomarker Combined Japan Integrated Staging Score

Kitai¹,

Kudo²,

Minami³

et al. 2008

Intervirology

View full text Add to dashboard Cite

Objectives: The Japan Integrated Staging (JIS) score has been reported to have good stratification ability in patients with hepatocellular carcinoma (HCC). However, the JIS score could not estimate malignant grade of HCC. The aim of this study was to evaluate the performance of a new staging system: the biomarker combined JIS (bm-JIS) which includes three tumor markers: α-fetoprotein (AFP), Lens culinaris agglutinin-reactive AFP and des-γ-carboxy prothrombin with the conventional JIS score. Methods: A total of 1,924 HCC patients were included in this study. We compared their overall survival, the stratification ability and suitability as a prognostic model according to the bm-JIS score and the conventional JIS score. Results: There were significant differences between the survival curves for all bm-JIS scores. For the conventional JIS scores of 0, 1, 2 and 3, the survival curves differed greatly according to the bm-JIS score (p < 0.0001). The independent homogenizing ability and the stratification value of the JIS score and the bm-JIS score determined by the likelihood ratio test using the Cox proportional hazard regression model showed the bm-JIS score to have a higher value(χ² = 717.348) than the JIS score (χ² = 668.91). Conclusions: The bm-JIS score showed superior stratification ability and thus was found to be a better predictor of the prognosis than the conventional JIS score, especially for the patients with good prognosis.

show abstract

“…Positive findings for such tumor markers have clinical implications for advance warning and appropriate management of patients with HCC [6,7,8,9,10]. In addition, the utility of these three tumor markers for the detection and the evaluation of tumor progression and the prognosis of patients with HCC in comparison to the use of each marker alone has been previously proposed in several reports [11,12,13,14,15,16]. …”

Section: Introductionmentioning

confidence: 99%

Validation of a New Prognostic Staging System for Hepatocellular Carcinoma: A Comparison of the Biomarker-Combined Japan Integrated Staging Score, the Conventional Japan Integrated Staging Score and the BALAD Score

Kitai¹,

Kudo²,

Minami³

et al. 2008

Oncology

View full text Add to dashboard Cite

Objectives: The conventional Japan Integrated Staging (c-JIS) score has been reported to effectively stratify patients with hepatocellular carcinoma (HCC). Recently, two new staging systems, the biomarker-combined JIS (bm-JIS) score and the BALAD score, have been proposed. Both staging systems include three tumor markers: α-fetoprotein (AFP), lens culinaris agglutinin-reactive AFP and des-γ-carboxy prothrombin specific for HCC. The aim of this study is to evaluate the performance of these three staging systems. Methods: A total of 1,173 HCC patients were included in this study. The stratification ability and prognostic predictive power were compared between these three staging systems. Results: These three staging systems effectively predicted the patient survival. When accounting for the best prognostic subgroup of each staging systems (i.e. score of 0), there were significant differences between the bm-JIS score and the BALAD score and, likewise, between the c-JIS score and the BALAD score. The likelihood ratio χ² test showed the highest value and the Akaike information criterion value was lowest in the bm-JIS score. Conclusions: The bm-JIS score showed good stratification ability and was thus demonstrated to be a better predictor of the prognosis than the c-JIS score and the BALAD score, especially for the patients with a good prognosis.

show abstract

Fucosylated fraction of alpha‐fetoprotein, L3, as a useful prognostic factor in patients with hepatocellular carcinoma with special reference to low concentrations of serum alpha‐fetoprotein

Abstract: The present study indicates that the L3 fraction before treatment serves as a useful prognostic indicator when the serum concentrations of AFP were very low.

Cited by 22 publications

References 26 publications

Fucosylated Fraction of Alpha-Fetoprotein as a Predictor of Prognosis in Patients with Hepatocellular Carcinoma After Curative Treatment

Fucosylated Fraction of Alpha-Fetoprotein as a Predictor of Prognosis in Patients with Hepatocellular Carcinoma After Curative Treatment

A New Prognostic Staging System for Hepatocellular Carcinoma: Value of the Biomarker Combined Japan Integrated Staging Score

Validation of a New Prognostic Staging System for Hepatocellular Carcinoma: A Comparison of the Biomarker-Combined Japan Integrated Staging Score, the Conventional Japan Integrated Staging Score and the BALAD Score

Contact Info

Product

Resources

About